Answer: I know it’s not D because the line is broken. If the line is not broken it means its greater than it less than
Step-by-step explanation:
Answer:
1) They will stop 10 times for a break
2) A baker can make 10 cakes
3) Tammy will distrubute 36 bags with 2 1/2 pounds of candy
Step-by-step explanation:
Let me know if you have any questions !
Hope it helps
The dimensions of the prism can be 2x, 2x+3 and x+6.
We first factor out the GCF of the trinomial. The GCF of the coefficients is 2. Each term has an x in common as well, so the GCF is 2x.
Factoring out the 2x, we have
2x(2x²+15x+18).
To factor the remaining trinomial, we find factors of 2*18=36 that sum to 15. 12*3 = 36 and 12+3 = 15. We split up 15x into 12x and 3x:
2x(2x²+12x+3x+18)
Now we group together the first two terms in parentheses and the last two:
2x((2x²+12x)+(3x+18))
Factor out the GCF of the first group:
2x(2x(x+6)+(3x+18))
Factor out the GCF of the second group:
2x(2x(x+6)+3(x+6))
Factoring out what these have in common,
2x(x+6)(2x+3)
Answer:
-1
Step-by-step explanation:
-4+-1+0+1=-4
4 divided by -4 = -1
Answer:
If we reject the null hypothesis based on the evidence, then our conclusion should be Option c.
If we do not reject the null hypothesis based on the evidence, then our conclusion should be Option a.
Step-by-step explanation:
We are given that the FDA wants to set up a hypothesis test to show that the new drug is safe before approving it by assuming it to be unsafe.
So, Null hypothesis, = New drug is unsafe
Alternate Hypothesis, = New drug is safe
<em>Now, if we reject the null hypothesis based on the evidence, then our conclusion should be that : </em>
There is sufficient evidence to believe that the new drug is safe because rejecting null hypothesis means that alternate hypothesis is accepted with required evidence.
<em>And If we do not reject the null hypothesis based on the evidence, then our conclusion should be that : </em>
There is insufficient evidence to believe that the new drug is safe because not rejecting null hypothesis means that we are not ready with enough evidence to assume that new drug is safe.